Table 3 Multivariate analysis investigating residual invasive tumour size by neoadjuvant treatment (adjusting for prognostic factors)

From: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

Factor

Estimate

s.e.

95% CI

P -value

Treatment

    

 CT alone vs CT+zoledronic acid

12

4.3

3.5, 20.4

0.0059

T-stage

    

 T2 vs T4

−20.7

14.7

−49.6, 8.3

0.2870

 T3 vs T4

2

4.5

−6.8, 10.8

 

Taxane regimen

 Yes vs no

11.9

5.1

1.9, 21.9

0.0204

Treatment duration

a

−0.2

0.1

−0.3, −0.1

0.0011

ER status

    

 Positive vs negative

10.2

5.4

−0.5, 21

0.0609

PgR status

    

 Positive vs negative

0.4

6.2

−11.9, 12.7

0.1466

 Unknown vs negative

−9.2

5.7

−20.5, 2.1

 

Menopausal status

 Pre vs post

−9.8

4.8

−19.3, −0.2

0.0567

 Unknown vs post

−16.5

8.3

−32.9, −0.1

 
  1. Abbreviations: CI=confidence interval; CT=chemotherapy; ER=oestrogen receptor.
  2. a Defined as time from the first chemotherapy to surgery (days); a negative estimate indicates tumour size decreasing with increasing treatment duration.
  3. Reference categories are shown in bold.
  4. A positive estimate indicates that the residual invasive tumour size is decreased in the reference category.
Back to article page